These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 20863951)

  • 21. Antiatherosclerotic effects of long-term maximally intensive statin therapy after acute coronary syndrome: insights from Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin Versus Atorvastatin.
    Puri R; Nissen SE; Shao M; Ballantyne CM; Barter PJ; Chapman MJ; Erbel R; Libby P; Raichlen JS; Uno K; Kataoka Y; Nicholls SJ
    Arterioscler Thromb Vasc Biol; 2014 Nov; 34(11):2465-72. PubMed ID: 25212234
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy, safety, tolerability, and pharmacokinetic profile of evacetrapib administered as monotherapy or in combination with atorvastatin in Japanese patients with dyslipidemia.
    Teramoto T; Takeuchi M; Morisaki Y; Ruotolo G; Krueger KA
    Am J Cardiol; 2014 Jun; 113(12):2021-9. PubMed ID: 24786356
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of early statin treatment on inflammation and cardiac events in acute coronary syndrome patients with low-density lipoprotein cholesterol.
    Kanadaşi M; Cayli M; Demirtaş M; Inal T; Demir M; Koç M; Avkaroğullari M; Dönmez Y; Usal A; Alhan CC; San M
    Heart Vessels; 2006 Sep; 21(5):291-7. PubMed ID: 17151816
    [TBL] [Abstract][Full Text] [Related]  

  • 24. C-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after maximally intensive statin therapy.
    Puri R; Nissen SE; Libby P; Shao M; Ballantyne CM; Barter PJ; Chapman MJ; Erbel R; Raichlen JS; Uno K; Kataoka Y; Nicholls SJ
    Circulation; 2013 Nov; 128(22):2395-403. PubMed ID: 24043299
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aggressive lipid-lowering is more effective than moderate lipid-lowering treatment in carotid plaque stabilization.
    Kadoglou NP; Sailer N; Moumtzouoglou A; Kapelouzou A; Gerasimidis T; Liapis CD
    J Vasc Surg; 2010 Jan; 51(1):114-21. PubMed ID: 19837545
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial.
    Rosenson RS; Hislop C; McConnell D; Elliott M; Stasiv Y; Wang N; Waters DD;
    Lancet; 2009 Feb; 373(9664):649-58. PubMed ID: 19231633
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study).
    LaRosa JC; Grundy SM; Kastelein JJ; Kostis JB; Greten H;
    Am J Cardiol; 2007 Sep; 100(5):747-52. PubMed ID: 17719314
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study.
    Kinlay S; Schwartz GG; Olsson AG; Rifai N; Leslie SJ; Sasiela WJ; Szarek M; Libby P; Ganz P;
    Circulation; 2003 Sep; 108(13):1560-6. PubMed ID: 12975259
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The sPLA2 Inhibition to Decrease Enzyme Release after Percutaneous Coronary Intervention (SPIDER-PCI) trial.
    Džavík V; Lavi S; Thorpe K; Yip PM; Plante S; Ing D; Overgaard CB; Osten MD; Lan J; Robbins K; Miner SE; Horlick EM; Cantor WJ
    Circulation; 2010 Dec; 122(23):2411-8. PubMed ID: 21098449
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of asymptomatic adults with elevated coronary calcium scores with atorvastatin, vitamin C, and vitamin E: the St. Francis Heart Study randomized clinical trial.
    Arad Y; Spadaro LA; Roth M; Newstein D; Guerci AD
    J Am Coll Cardiol; 2005 Jul; 46(1):166-72. PubMed ID: 15992652
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alternate-day versus daily atorvastatin in coronary artery disease: a randomized study.
    Rifaie O; Zahran A; Nammas W
    Anadolu Kardiyol Derg; 2012 Mar; 12(2):90-6. PubMed ID: 22281786
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy.
    McKenney JM; Koren MJ; Kereiakes DJ; Hanotin C; Ferrand AC; Stein EA
    J Am Coll Cardiol; 2012 Jun; 59(25):2344-53. PubMed ID: 22463922
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study.
    Kinlay S; Schwartz GG; Olsson AG; Rifai N; Sasiela WJ; Szarek M; Ganz P; Libby P;
    Circulation; 2004 Jul; 110(4):386-91. PubMed ID: 15262833
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design of the randomized, placebo-controlled evolocumab for early reduction of LDL-cholesterol levels in patients with acute coronary syndromes (EVOPACS) trial.
    Koskinas KC; Windecker S; Buhayer A; Gencer B; Pedrazzini G; Mueller C; Cook S; Muller O; Matter CM; Räber L; Heg D; Mach F;
    Clin Cardiol; 2018 Dec; 41(12):1513-1520. PubMed ID: 30421481
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Substudy.
    Gibson CM; Pride YB; Hochberg CP; Sloan S; Sabatine MS; Cannon CP;
    J Am Coll Cardiol; 2009 Dec; 54(24):2290-5. PubMed ID: 19958964
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease.
    Conard SE; Bays HE; Leiter LA; Bird SR; Rubino J; Lowe RS; Tomassini JE; Tershakovec AM
    Am J Cardiol; 2008 Dec; 102(11):1489-94. PubMed ID: 19026302
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial.
    Ballantyne CM; Houri J; Notarbartolo A; Melani L; Lipka LJ; Suresh R; Sun S; LeBeaut AP; Sager PT; Veltri EP;
    Circulation; 2003 May; 107(19):2409-15. PubMed ID: 12719279
    [TBL] [Abstract][Full Text] [Related]  

  • 38. On-Statin Resistin, Leptin, and Risk of Recurrent Coronary Events After Hospitalization for an Acute Coronary Syndrome (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Study).
    Khera AV; Qamar A; Murphy SA; Cannon CP; Sabatine MS; Rader DJ
    Am J Cardiol; 2015 Sep; 116(5):694-8. PubMed ID: 26119654
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pregnancy-associated plasma protein-A elevation in patients with acute coronary syndrome and subsequent atorvastatin therapy.
    Miedema MD; Conover CA; MacDonald H; Harrington SC; Oberg D; Wilson D; Henry TD; Schwartz RS
    Am J Cardiol; 2008 Jan; 101(1):35-9. PubMed ID: 18157962
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma PCSK9 levels and clinical outcomes in the TNT (Treating to New Targets) trial: a nested case-control study.
    Huijgen R; Boekholdt SM; Arsenault BJ; Bao W; Davaine JM; Tabet F; Petrides F; Rye KA; DeMicco DA; Barter PJ; Kastelein JJ; Lambert G
    J Am Coll Cardiol; 2012 May; 59(20):1778-84. PubMed ID: 22575316
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.